Antares Pharma Inc. (NASDAQ:ATRS) stock is up 2.55% to close at $2.81 on Thursday, 05/21/20. ATRS stock is higher by $0.07 from the previous closing price of $2.74 on volume of 905993 shares. In the meantime, ATRS was trading in the Healthcare sector, the stock is trading -45.22% low as compared to its 52-week high price and 75.62% high as compared to its 52-week low price. Of example, both the price and the high and low measurements of 52 weeks will give you a clear image for determining the price track. The firm has a Weighted Alpha of -4.5. A positive weighted alpha shows that over the past year the stock has risen. A negative means that over the same period the stock is down.What do the Analysts Think?
Over the last 12 months, Antares Pharma Inc. (ATRS) stock has fallen by -0.35 percent, and Wall Street analysts’ average rating is a Buy. ATRS stock has an average target price of $6.25 in addition to the average rating from Wall Street analysts.
Estimates of future earnings are probably the most important feedback when attempting to evaluate a company. Analysts can then use cash flow analysis to approximate fair value for a company by placing estimates on a company’s earnings for certain periods. In case of Antares Pharma Inc. (ATRS), the Consensus Average Estimate of EPS for fiscal year 12/2020 according to 6 analysts is at $0.02 per share. The high EPS estimate is $0.08 per share and the low estimate is -$0.03 per share. The Average estimate indicates the 300.00% growth as compared to the prior year estimated EPS of -$0.01 per share.
Antares Pharma Inc. also currently has an EPS Growth of 69.90 percent for current year, showing analysts have bullish about their potential for near-term earnings. EPS growth was 45.90 percent over the past five years, along with sales growth of 36.10 percent over the past five years. Next year’s EPS growth is estimated at 414.89%.
The performance of the stocks typically measures, how much a stock gain or lose its value during different time spans. Antares Pharma Inc. (NASDAQ:ATRS) has achieved around 4.85% in the last 30 days and around -20.40% over the last three months. The stock exposed return of +32.55% over the period of last 5 years and recorded return of 9.34% over a week. In the last 6 months, the stock has been observed at -36.71% return.Tracking the Profitability and Valuation Ratios
Tracking productivity test, the company profit margin at 0.90% and the operating margin at 3.40%. The organization reported a 59.20 percent Gross Margin. The profit margin ratio, also referred to as the revenue ratio or gross profit ratio, is a productivity equation that dealings the amount of net income gained with each dollar in revenues produced by contrasting the company’s net income and net sales. The higher ratio means the more profit and vice versa.
As of the last trading session the stock has achieved a market cap of $470.73M. Market capitalization is the cumulative dollar value of all of a company’s outstanding shares and is used to quantify businesses and consider their overall market value. The P/E ratio of Antares Pharma Inc. (NASDAQ:ATRS) is noted at 401.43. Price-to-earnings ratio is a common measure of the current share price of a business relative to its per-share profits (ttm). Forward P/E is standup at 11.61. Forward price-to-earnings ratio calculated utilizing projected earnings for the next financial year’s P/E estimate. The stock has attained Price-to-sales ratio of 3.52 replicates the cost to be found on sales by the market. The firm maintained Price-to-book ratio of 8.52, which is used to equate the market value of a stock with its book value.How Insiders are Trading the Stock?
SAMSON MARVIN, Director of Antares Pharma Inc. (ATRS) sold 56 shares of firm against total value of $252 at the rate of $4.50 on Jan 10. SAMSON MARVIN, Director of Antares Pharma Inc. (ATRS) sold 99,944 shares of firm against total value of $459,242 at the rate of $4.59 on Jan 02. SAMSON MARVIN, Director of Antares Pharma Inc. sold 150,000 shares of firm against total value of $706,500 at the rate of $4.71 on Dec 23. Mostly, the investors and traders are looking for stocks with the high ownership of company’s management because they think that when the company’s management is the major shareholder of a firm, the management will run the business for itself and they will never act those activities which are against their interests and they will always try to create shareholder value in the long-term. Currently, 2.10% of Antares Pharma Inc.‘s shares possessed by insiders, while 42.70% shares possessed by financial institutions.